






Changes in the penetration rate of biosimilar infliximab within Japan using a 












































Chapter 1 Data extraction and patient background 
Chapter 2 The penetration rate of biosimilar infliximab by fiscal year  
Chapter 3 The penetration rate of biosimilar infliximab with or without subsidy for intractable 
disease by target diagnosis 


















2019年 11月 15日の時点で、日本の医薬品医療機器総合機構（PMDA）は 11の有効成
分（21のバイオシミラー）を承認している。しかしながら、日本におけるバイオシミラー
の浸透度は十分とは言い難く、有効成分ごとの浸透度に差があることが明らかとなっている。
































院の約 24％をカバーしている。2020年 6月時点で、約 3,300万人の累積患者のデータが含
まれている。 
データ抽出：2008年 4月 1日から 2019年 3 月 31日までに収集されたデータを、患者
























2008年 4月から 2019年 3月までにMDVデータベースでインフリキシマブの処方記録
（先行品またはそのバイオシミラー）のある合計 13,302人の患者が特定され、そのうち


























































































As therapeutic agents, biologic medications bring about tremendous benefits for serious life-
threatening and chronic diseases.1 In Japan, several biologic medications have been 
approved since insulin was f irst approved as a biologic medication in 1985.2 While biologic 
medications offer considerable therapeutic benef its, they have increased medical 
expenditure. Drug prices of  recently-approved drugs, including biologics, anti-cancer drugs, 
and anti-hepatitis C drugs, are especially high.3,4 The Japanese national health-care system 
is currently facing difficulties due to an population aging and the introduction of new high-cost 
drugs, which may jeopardize its integrity. As such, expanding the usage of  biosimilars has 
been an anticipated to be a solution for reducing national health-care costs, given that they 
are priced approximately 30% cheaper than their reference products within the Japanese 
national health insurance drug price system.5 A number of  biosimilars have been approved 
as highly similar to their reference products, following studies required to show that they 
have no clinically signif icant differences in safety, purity, or potency (safety and 
ef fectiveness) compared with the reference product.6,7 Considering that only biosimilar 
products that meet rigorous standards are approved by regulatory authorities,8 physicians 
and patients should have no concern regarding their use. However, the truth of  the matter is 
that some physicians lack the conf idence to prescribe biosimilars, while patients receive 
insuf f icient explanations regarding biosimilars from physicians.9 As of November 15, 2019, 
the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has approved 21 
biosimilar marketing authorizations of  11 reference biologic products.10 Since 2018, the 
Japanese Ministry of  Health, Labour and Welfare (MHLW) has issued policies leading to 
awareness regarding biosimilars.11 However, previous research suggests that biosimilars 
had insuf f icient penetration rates within Japan. Discrepancies in penetration rates have been 
observed among four biosimilar products (insulin glargine, f ilgrastim, inf liximab, and 
rituximab), which have been available in Japan within the period f rom 2012 to 2018. Among 
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them, in the second half  of  2018, biosimilar f ilgrastim had the highest penetration rate at 80% 
and biosimilar inf liximab had the lowest rate at 5.3%.12 
Inf liximab is a chimeric monoclonal antibody against tumor necrosis factor alpha (TNF-α) 
used for treatment of  rheumatoid arthritis (RA), Crohn’s disease (CD), ulcerative colitis (UC), 
psoriasis (Ps), Behçet’s disease with uveitis, ankylosing spondylitis, neuro-Behçet’s disease, 
and Kawasaki disease.13 The f irst biosimilar of  infliximab was approved by the PMDA in 
2014 for RA, CD, and UC.10 However, 5 years af ter its approval, the biosimilar has yet to 
overtake reference inf liximab treatment. One possible reason is that Japan has a robust 
health-care system that includes a high-cost medical expense benef it program (Eligibility 
Certif icate for Ceiling-Amount Application) and a medical care subsidy system for intractable 
diseases. The high-cost medical expense benef it system pays off any amount exceeding a 
f ixed monthly limit to prevent excessive f inancial burden on the patient.14,15 The intractable 
disease system, formerly called the specific diseases program, has two major components: a 
research grant for intractable diseases and a medical cost subsidy for intractable diseases. 
Patients covered by the subsidy scheme receive waivers for all or some co-payments for 
medical bills to eliminate the f inancial barrier to health services, thereby encouraging a larger 
number of  patients with intractable diseases to register in the research program.16 Among 
the indications for biosimilar inf liximab, CD, UC, and some Ps are included in target diseases 
of  the intractable system.17 The subsidy systems are believed to reduce motivation for using 
biosimilars, given that patients’ medical expenditure would remain the same regardless of  
biosimilar use. However, not enough data have been available to examine current 
circumstances surrounding the clinical use of  biosimilar inf liximab within Japan, including 
patient characteristics, penetration rate of  biosimilars according to department, and the 
relationship between biosimilar penetration rate and subsidy for intractable diseases.  
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Results 
Chapter 1 Data extraction and patient background 
A total of  13,302 patients with inf liximab records (reference and/or its biosimilar) were 
identif ied in the MDV database f rom April 2008 to March 2019, among whom 10,597 started 
inf liximab treatment af ter April 1, 2013. Meanwhile, 772 patients without target disease 
diagnosis records and 107 patients with inf liximab records before the target disease 
diagnosis record were excluded. Overall, data f rom 9,735 patients included in the study 
population were extracted (Figure 1). 
 
 Figure 1 Patient flow chart 
 
Abbreviations: MDV, Medical Data Vision; RA, rheumatoid arthritis; CD, Crohn's disease; 
UC, ulcerative colitis; Ps, psoriasis; ICD, International Classif ication of Diseases; N, number 
of  patients.  
*Target diseases: RA (ICD10 Code: M05, M06), UC (ICD10 Code: K51), CD (ICD10 Code: 





A total of  8,950 (91.9%) and 785 (8.1%) patients were categorized into the reference and 
biosimilar groups, respectively. Among those in the biosimilar group, 490 patients had only a 
biosimilar record, 274 had switched f rom reference to biosimilar inf liximab, and 21 had 
switched f rom biosimilar to reference inf liximab. The numbers (proportion) of  patients 
according to target disease diagnosis were 3,073 (31.6%), 3,797 (39.0%), 3,023 (31.1%), 
and 735 (7.6%) for RA, CD, UC, and Ps, respectively. Patient characteristics of the reference 
and biosimilar groups are detailed in Table 1. 
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Table 1 Patient characteristics 
 Reference (n=8,950) Biosimilar (n=785) 
Age, mean (SD) 44.6 (17.65) 52.9 (17.10) 
0–9 years 20 (0.2%) 0 (0.0%) 
10–20 years 628 (7.0%) 16 (2.0%) 
20–29 years 1,487 (16.6%) 85 (10.8%) 
30–39 years 1,616 (18.1%) 85 (10.8%) 
40–49 years 1,769 (19.8%) 134 (17.1%) 
50–59 years 1,291 (14.4%) 130 (16.6%) 
60–69 years 1,267 (14.2%) 184 (23.4%) 
70–79 years 731 (8.2%) 133 (16.9%) 
≥80 years 139 (1.6%) 18 (2.3%) 
Male 5,006 (55.9%) 344 (43.8%) 
Receiving subsidy for intractable disease 5,718 (63.9%) 240 (30.6%) 
Target disease diagnosis RA 2,631 (29.4%) 442 (56.3%) 
CD 3,619 (40.4%) 178 (22.7%) 
UC 2,851 (31.9%) 172 (21.9%) 
Ps 680 (7.6%) 55 (7.0%) 




IP 463 (5.2%) 66 (8.4%) 
COPD 34 (0.4%) 4 (0.5%) 
DM 22 (0.2%) 8 (1.0%) 
Hypertension 11 (0.1%) 0 (0.0%) 
Switch to other biologics 1,484 (16.6%) 107 (13.6%) 
Switch to JAK inhibitors 65 (0.7%) 13 (1.7%) 
Hospitalization 3,829 (42.8%) 305 (38.9%) 
Abbreviations: SD, standard deviation; RA, rheumatoid arthritis; CD, Crohn's disease; UC, 
ulcerative colitis; Ps, psoriasis; IP, interstitial pneumonia; COPD, chronic obstructive 
pulmonary disease; DM, diabetes mellitus; JAK Janus kinase.  
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Chapter 2 The penetration rate of  biosimilar inf liximab by fiscal year  
Biosimilar penetration rates according to FY were 0.8%, 5.2%, 8.0%, 11.8%, and 22.5% in 
2014, 2015, 2016, 2017, and 2018, respectively. All biosimilar inf liximab penetration rates 
according to target disease diagnosis gradually increased from 2014 to 2018 (Figure 2). 
 
Figure 2 The penetration rate of biosimilar infliximab by fiscal year 
 
Abbreviations: Ref , reference product; BS, biosimilar; N, number of  patients; RA, 
rheumatoid arthrosis; CD, Crohn's disease; UC, ulcerative colitis; Ps, psoriasis. 
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Chapter 3 The penetration rate of  biosimilar inf liximab with or without subsidy for intractable 
disease by target diagnosis 
Biosimilar penetration rates throughout the whole study period according to diagnosis (with 
or without subsidy) were 14.4% (with, 4.1%; without, 16.4%) for RA, 4.7% (with, 3.7%; 
without, 10.6%) for CD, 5.7% (with, 4.5%; without, 13.5%) for UC, and 7.5% (with, 4.4%; 
without, 8.2%) for Ps (Table 2). 
 
Table 2 Number of  patients receiving the reference inf liximab or its biosimilar for target 
disease diagnosis (whole, with or without subsidy for intractable disease) throughout the 
study period f rom 2014 to 2018 
Target 
disease 











RA Whole 3,073 2,631 442 14.4% 
 
With 508 487 21 4.1% 
 
Without 2,565 2,144 421 16.4% 
CD Whole 3,797 3,619 178 4.7% 
 
With 3,241 3,122 119 3.7% 
 
Without 556 497 59 10.6% 
UC Whole 3,023 2,851 172 5.7% 
 
With 2,622 2,504 118 4.5% 
 
Without 401 347 54 13.5% 
Ps Whole 735 680 55 7.5% 
 
With 136 130 6 4.4% 
 
Without 599 550 49 8.2% 
Abbreviations: RA, rheumatoid arthritis; CD, Crohn's disease; UC, ulcerative colitis; Ps, 
psoriasis. 
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Chapter 4 The penetration rate of  biosimilar inf liximab by department in each indication 
The rheumatology department had the largest number of  patients prescribed infliximab 
(reference and/or biosimilar) for RA in 2018, followed by internal medicine and orthopedic 
surgery. For both CD and UC, the gastroenterology department had the largest number of  
patients prescribed inf liximab, followed by internal medicine and gastrointestinal surgery. For 
Ps, the dermatology department had the largest number of  patients prescribed infliximab, 
followed by internal medicine and rheumatology. The number of  patients receiving biosimilar 
inf liximab and biosimilar penetration rates according to diagnosis and department increased 







Figure 3 Annual changes in biosimilar penetration rate for each target disease by 
department f rom 2014 to 2018 
A, rheumatoid arthritis. B, Crohn’s disease. C, ulcerative colitis. D, psoriasis.  
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Discussion 
This is the f irst study to describe whether patients with RA, CD, UC, and Ps received 
inf liximab and/or its biosimilars and whether or not they received subsidy for intractable 
diseases. Reference inf liximab (Remicade®), which was launched in Japan in 2002, has 
been widely used for inf lammatory diseases such as RA, CD, and UC. Its f irst biosimilar 
(inf liximab BS1, Nippon Kayaku, Celltrion) was approved by the PMDA in 2014, while the 
second (inf liximab BS2, Nichiiko, Yakuhan Pharma) and third (inf liximab BS3, Pf izer) 
biosimilars were approved in 2017 and 2018, respectively. Given that the extracted data 
were f rom April 2013 to March 2019, the database employed here mainly contained data for 
BS1 and BS2.10 It is unlikely that there are dif ferences in disease entry or demographics of 
disease between BS1 and BS2 since patients in Japan have the right to choose any medical 
institution, regardless of  disease sensitivity or severity, and the price of  these biosimilars is 
the same, based on a price policy listed on the national health insurance program. 
Patient background, characteristics, comorbidity, and hospitalizations were similar 
between the reference and biosimilar groups, except for rate of  subsidy for intractable 
disease. Although the biosimilar group was older (mean, 52.9 years) than the reference 
group (mean, 44.6 years), this was partly because biosimilars were rarely used for patients 
under 20 years of  age (Table 1). In the biosimilar group, 62.4% of  the patients (490 of  785) 
had only biosimilar records, while 34.9% (274 of  785) had records of  switching from 
reference inf liximab. This indicates that biosimilar inf liximab was more of ten prescribed for 
patients who started inf liximab treatment than for those who had already been prescribed the 
reference product. 
Inf liximab was prescribed mostly for patients with CD (39.0%), followed by RA (31.6%), 
UC (31.1%), and Ps (7.6%) during the study period. Biosimilar inf liximab penetration rates 
increased annually f rom 0.8% in 2014 to 22.5% in 2018, a trend observed for all indications 
(Figure 2). The penetration rate determined herein was comparable to that presented in 
previous reports f rom the European Union, which showed a total market penetration rate of  
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24% in 2017.32 In particular, penetration rates greatly increased during 2017 and 2018. One 
reason for this could be the clear statement in the Japanese government-approved policy 
document of  the Council, published on June 9, 2017. While this policy enhanced supporting 
measures for the research and development of  biopharmaceuticals and biosimilar 
pharmaceuticals, it disclosed the ef fective amount of optimization of medical costs and value 
share of  biosimilar pharmaceuticals, and aimed to double the number of  biosimilar 
pharmaceuticals (number of  ingredients basis) by the end of  the f inancial year 2020.33 Taking 
these measures into account, the medical associations and pharmaceutical companies have 
def initely made an ef fort to promote biosimilars. However, there is a considerable 
discrepancy when comparing the volume-based market share of  inf liximab biosimilar with 
that of  other counties. According to previous research, the market share of  inf liximab 
biosimilars reached approximately 89% in the UK, followed by France (48%), and Korea 
(35%), whereas it was only 6% in Japan, based on the values for quarter one of  2018.34 
Previous studies have shown an obvious discrepancy among the penetration rates of  four 
biosimilar products in Japan, namely insulin glargine, f ilgrastim, infliximab, and rituximab, 
among which the biosimilar of  filgrastim had the highest penetration rate of  80%, whereas 
the biosimilar of  infliximab had the lowest penetration rate of  5.3%.12 This discrepancy may 
be due to dif ferences between products in aspects such as the number of  indications and 
prescriber expertise. Although f ilgrastim is prescribed mainly by hematologists for hematic 
cancer in the short term, inf liximab is prescribed not only by rheumatologists for RA but also 
by gastroenterologists for UC and CD over the long-term. This means greater ef fort is 
needed for physicians to gain understanding and experience in the use of  inf liximab 
biosimilar than for f ilgrastim biosimilar, without incentives, as well as for patients to accept a 
switch to the biosimilar version. Moreover, intractable disease systems may af fect the 
motivation to use biosimilars. Filgrastim is prescribed mainly to patients with non-intractable 
diseases, whereas inf liximab is prescribed mainly to those with intractable disease, such as 
CD, UC, or Ps. The current study also explored the relationship between biosimilar 
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penetration rate and subsidy for intractable diseases. As expected, patients receiving 
subsidy for intractable diseases had much lower biosimilar penetration rates than those who 
did not, regardless of  indication (Table 2). Although UC, CD, and some Ps have been 
designated as intractable disease, RA is not. The current f indings could suggest that 
biosimilar inf liximab penetration rates were highest in rheumatology departments. The 
intractable designation is an excellent system that reduces patient costs for the treatment of  
intractable diseases. Accordingly, those patients recognized as having a designated 
intractable disease need not pay over the cap on the total amount due each month. Through 
this system, patients with designated intractable diseases may focus on their treatment 
without considering treatment costs—part of a health-care system the Japanese government 
takes pride in globally. This system, however, causes patients to lack motivation for using 
biosimilars17,35,36 given that the use of  biosimilars instead of reference biologics does not 
decrease patient costs. Had treatment costs become cheaper, the use of  biosimilars would 
certainly have increased due to the potential savings with no loss in benef its. Thus, the 
generous Japanese health-care system could be one of  the barriers toward expanding 
biosimilar use. 
In spite of  RA not covered by the intractable disease subsidy some treated RA patients 
were in receipt of  subsidy. It anticipated that these particular patients had other comorbid 
diseases, such as rheumatoid vasculitis, which attracted an intractable disease subsidy. Not 
all patients with UC or CD received subsidies for intractable disease, perhaps because they 
failed to satisfy the disease severity criteria for designated intractable diseases. Some 
patients may also receive a medical expense subsidy other than that for intractable diseases. 
The rheumatology departments of  Japanese hospitals had the highest biosimilar 
penetration rates in 2018 among all indications and departments (59.0%). However, the 
number of  patients receiving biosimilars has remained stable since 2015 (Figure 3A). 
Therefore, an apparent increase in penetration rate rather than biosimilar use can be inferred. 
This result is reasonable considering the current RA treatment situation, where there is less 
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opportunity for infliximab treatment given the number of  new classes of  available drugs, such 
as additional biologic disease-modifying antirheumatic drugs, TNF inhibitors, sarilumab (an 
anti-interleukin-6 receptor antibody that targets the same molecule as tocilizumab), and 
tofacitinib and baricitinib (Janus kinase inhibitors).37 
Penetration rates for CD and UC had an increasing tendency across each department in 
Japanese hospitals, with the timing of  the increase being slightly later than that for RA 
(Figures 3B and 1C). The same tendency was observed for Ps in dermatology departments 
(Figure 3D). As mentioned earlier, obtaining direct benef its from using biosimilar inf liximab 
remains dif f icult given that CD and UC have been designated as intractable diseases. 
However, the signif icance of using biosimilars lies with not only reducing the burden on 
patients but also contributing toward a sustainable health-care system impervious to time.9 
To control health-care expenditure, especially in Europe, there are strict policies on the use 
of  high-cost drugs, based on Health Technology Assessment. On the other hand, in Japan, 
although drug prices are listed on the national health insurance program, there is no limit to 
the use of  high-cost drugs, regardless of disease history or severity. In the current situation, 
controlling the increase in medical expenditures throughout Japan, with an aging population, 
remains an urgent concern. The Japanese government consistently established policies that 
pushed biosimilar use in Japan f rom 2017 to 2019,33,38,39 while educational seminars for 
health- care professionals and patients by the MHLW started in 2018.11 In 2020, the national 
price of  reference inf liximab per 100-mg vial was 75,009 Japanese Yen (JPY) and biosimilar 
inf liximab was 43,229 JPY. Therefore, by using the biosimilar, the Japanese government 
could potentially save 30,384 JPY per vial.40 MHLW reported that the total number of  
inf liximab reference and biosimilar was approximately 962,000 vials per year in f inancial year 
2016.41 If  biosimilar inf liximab penetration increases to the same extent as biosimilar 
f ilgrastim, to 80%, the saving is estimated to be approximately 24,457 million JPY per year. 
With the promotion of biosimilars in mind, members of  the pharmaceutical industry 
established the Japan Biosimilar Association in 2016 to create a biosimilar-f riendly 
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environment for both the development and appropriate usage of  biosimilars in Japan. The 
association provides educational opportunities and materials for health-care professionals 
and patients. We believe that these activities would be ef fective in increasing the penetration 
rate of  biosimilar inf liximab. Therefore, continuously promoting the appropriate use of 
biosimilars while understanding the signif icance of these activities is important. We believe 
that our f indings could help the government and associations to establish new policies. 
 
Limitations of the Study 
The present study has several limitations worth noting. First, using claims data may af fect 
the validity and reproducibility of our research results. Although the MDV database covers 
approximately 24% of  all DPC hospitals in Japan, our results might not show the current 
national situation of  biosimilar inf liximab. However, we believe that the current f indings 
represent at least the current status of  DPC hospitals, given that inf liximab is an intravenous 
product prescribed in almost all DPC hospitals. Moreover, the use of  biosimilar inf liximab in 
DPC hospitals could be one key factor that determines the introduction timeline and 
penetration of  each biosimilar in Japan.8 Therefore, our results may be helpful in 
understanding the current situation of  biosimilars in Japan. Second, this study identified 
patients based on both the diagnostic code present in the claims data and prescription 
records of  inf liximab. In actual clinical practice, some coding may not be accurately recorded, 
some cases may have been misdiagnosed, or several professionals may have dif ferent 
coding patterns. Thus, the possibility of including misclassified patients cannot be ruled out. 
Despite the aforementioned limitations, the MDV database remains useful and provides the 





The present study described the current situation of  biosimilar inf liximab according to 
diagnosis in Japan using a claims database. Accordingly, the reference and biosimilar 
groups showed similar patient characteristics. Moreover, the overall penetration rate of  
biosimilar inf liximab has been gradually increasing since its indication in 2014, with rates 
reaching 22.5% by 2018. Patients receiving subsidy for intractable diseases had much lower 
biosimilar penetration rates than those who did not, across all target disease diagnosis. 
Rheumatology, gastroenterology, and internal medicine are the primary departments that 
prescribe biosimilar inf liximab. 
 
Disclosure 
Tsugumi Matsumoto and Takanori Tsuchiya are employees of Pfizer Japan Inc. and hold stocks 
in the same company. All other authors of this manuscript declare that they have no conflicts of 
interest.
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Materials and Methods 
Study Design and Data Source 
This retrospective, descriptive study utilized the Medical Data Vision Inc., Ltd. (MDV Inc.) 
database, a nationwide hospital-based database that contains health claims data, 
administrative data, and Diagnosis Procedure Combination (DPC) data f rom more than 420 
Japanese acute hospitals (covering 24% of  DPC hospitals). DPC is a novel medical 
reimbursement system introduced in 2003 only for hospital inpatients.18 Within the DPC 
system, detailed data, such as medical treatment, procedures, diagnosis, department, and 
intractable disease status, are uniformly formatted on a daily basis according to diagnosis.19 
In DPC hospitals, although outpatient care is not covered by the DPC system, it is included 
in a fee-for-service payment system; therefore, the MDV database captures both inpatient 
and outpatient data. As of  June 2020, the MDV database contained anonymized patient 
identif ier, age, gender, diagnosis, medical procedures, prescriptions, inpatient/outpatient 
status, intractable disease designation status, total medical cost, and laboratory data of 
nearly 33 million cumulative patients. Many research articles have utilized the MDV database 




Data collected f rom April 1, 2008 were used as patient background information, whereas 
data collected between April 1, 2013 and March 31, 2019 were used for analysis. The quality 
of  the data within the database has been regularly assessed by MDV Inc. 
 
Definition of Target Disease Diagnosis 
Target disease diagnoses were identif ied based on the International Statistical Classif ication 
of  Diseases and Related Health Problems 10th Revision (ICD10). Accordingly, RA (M05, 
M06), CD (K50), UC (K51), and Ps (L40) were def ined as target disease diagnoses given 
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that they had been approved by the MHLW as indications for biosimilar inf liximab during the 
data extraction period. 
 
Study Population 
Patients prescribed inf liximab (reference inf liximab and/or its biosimilar) af ter April 1, 2013 
were included as the study population. However, records regarding biosimilars were 
available only af ter November 2014 when the f irst biosimilar of infliximab had been launched 
in Japan. Patients without target disease diagnosis records or with records of inf liximab use 
before target disease diagnosis were excluded. The sex and age of  those with two or more 
target disease diagnosis records were determined based on the f irst target diagnosis record. 
On the other hand, data regarding the number of  target disease diagnoses and biosimilar 
penetration rates according to diagnosis or department were included in each analysis set of  
target disease diagnosis. Patients who satisfied the inclusion criteria were divided into two 
groups: the reference inf liximab group and the inf liximab biosimilar group. Those who had at 




Statistical analyses were conducted using Statistical Analysis System Version 9.4 (SAS 
Institute Inc., Cary, NC, USA). All study variables were descriptively examined. No statistical 
tests were performed given that the current study aimed to describe only the current situation 
of  biosimilar inf liximab and was not intended to compare among target populations or target 
disease diagnoses. 
The following patient characteristics were examined: sex, age, subsidy for intractable 
diseases, multiple target diseases, comorbidity diseases [Interstitial pneumonia (J84), 
chronic obstructive pulmonary disease (J44), diabetes (E10, E20), and hypertension (I15)], 
and hospitalization in the reference and biosimilar groups. Subsidies for intractable diseases 
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were identif ied through receipt names/codes, which indicated intractable disease outpatient 
guidance management fees (113002910) or intractable disease patients, and other 
hospitalization care add-on fees (190101770) af ter the diagnosis date of the target disease. 
Patients with multiple target diseases were identif ied as those with two or more target 
disease diagnoses prior to the f irst infliximab treatment. Any disease diagnosed af ter patients 
received their f irst inf liximab treatment was not considered as a target disease. Biosimilar 
penetration rate was calculated based on the number of  patients who met the inclusion 
criteria and described per target disease diagnosis, subsidy for intractable disease, and f iscal 
year (FY) f rom April to March based on the f irst inf liximab treatment date. Changes in 
penetration rates per department were described for each target disease, while the top three 
departments with the highest number of  inf liximab records in 2018 (reference and/or 
biosimilar) were determined. 
 
Ethics Approval 
This study utilized a subject-level, electronic, health-related database released and 
maintained by MDV Inc. that protected the identity of individuals. MDV Inc. is permitted to 
use such anonymized data under a data transfer contract with its client health insurers. The 
current study complies with the “Ethical Guidelines for Epidemiological Research” 
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